New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine.
The findings from a double blinded randomized a Phase IIb/IIIa study combining nimotuzumab with gemcitabine in 192 patients with locally advanced or metastatic pancreatic cancer patients was recently published in the Annals of Oncology (Issue 10, 1 Oct 2017).
A total of 192 patients were randomly assigned to receive either nimotuzumab plus gemcitabine, or gemcitabine alone, with 1-year overall survival rates of 34% versus 19%, and median overall survival durations of 8.6 months versus 6.0 months, respectively (HR = 0.69; P = 0.0341). In addition progression free survival durations was observed at 4.43 months in the treatment arm versus 3.47 months in the control (HR = 0.68; P = 0.0163).
In a sub-group analysis, patients with pancreatic cancer KRAS-wild-type disease who received nimotuzumab had significantly longer overall survival than those with pancreatic cancer KRAS-mutant disease (11.6 months versus 5.6 months).
The randomized study showed that nimotuzumab in combination with gemcitabine is safe and well tolerated and that the 1-year OS and PFS rates for the entire population were significantly improved. The study met its primary objectives.
To access the full publication please visit: https://academic.oup.com/annonc/article-abstract/28/10/2429/3926574?redirectedFrom=fulltext
The clinical trial was sponsored and lead by Oncoscience Gmbh. The study ID was: OSAG-101-PCS-07